Reuters logo
BRIEF-Takeda, Seattle Genetics announce Lancet publication
June 7, 2017 / 12:19 PM / 4 months ago

BRIEF-Takeda, Seattle Genetics announce Lancet publication

June 7 (Reuters) - Takeda Pharmaceutical Co Ltd:

* Takeda and Seattle Genetics announce Lancet publication of phase 3 alcanza clinical trial data of adcetris (brentuximab vedotin) for CD30-positive cutaneous t-cell lymphoma

* Takeda - ‍takeda plans to begin to submit data from alcanza trial to regulatory agencies in its territories in 2017​

* Takeda - ‍Seattle Genetics plans to submit these data as part of a supplemental biologics license application to FDA in mid-2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below